(MENAFNEditorial)
With a growing and ageing population Vietnam plays host to an attractive target for pharmaceutical and healthcare growth. While per capita spending remains low and current healthcare infrastructure appears strained access to healthcare coverage is steadily increasing.
Headline Expenditure Projections
* Pharmaceuticals: VND69297bn (USD3.30bn) in 2013 to VND80730bn (USD3.80bn) in 2014; +17.0% in local currency terms and +16.2% in US dollar terms. Forecast unchanged from previous quarter.
* Healthcare: VND222374bn (USD10.57bn) in 2013 to VND254679bn (USD11.99bn) in 2014; +14.7% in local currency terms and +13.9% in US dollar terms. Forecast unchanged from previous quarter.
Full Report Details at
- http://www.fastmr.com/prod/944832_vietnam_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=101
Risk Reward Index:
Vietnam's Pharmaceutical Risk/Reward Index (RRI) score for Q115 is 49.1 out of the maximum 100 in our newly improved RRI system. The country scored above average for some indicators and sub-indicators including overall market expenditure sector value growth and pensionable population. Consequently with this moderate score Vietnam is ranked 11th behind India out of the 19 key markets in Asia Pacific.
Key Trends And Developments
* In December the EU entered a financial agreement with Vietnam to fund EUR114mn (USD141mn) for the second phase of the EU Health Sector Policy Support Programme (EU-HSPSP-2) in the country. The agreement aims to support Vietnam in restructuring its health sector and implementing reform plans between 2015 and 2017 by reducing sustainable poverty and creating harmonious growth in country's healthcare sector.
* In December it was announced that by 2020 locally manufactured drugs will account for 80% of Vietnam's pharmaceutical sector according to Drug Administration of Vietnam Head Truong Quoc Cuong. Under the 2020 plan the health ministry will focus on producing 20 materials along with increasing the share of domestically manufactured medicines to replace foreign drugs. The sector will aim to produce generic medicines and the...
The Vietnam Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Vietnam Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Vietnam pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for Vietnam to test other views - a key input for successful budgeting and strategic business planning in the Vietnamese pharmaceutical and healthcare market.
* Target business opportunities and risks in the Vietnamese pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Vietnam.
* Assess the activities strategy and market position of your competitors via our Company Profiles (inc. SWOTs KPIs and latest activity) and Competitive Landscape Tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:
Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).Patented Drug Market: Prescription drug sales (USDbn & % of total sales).Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).OTC Drug Market: OTC sales (USDbn & % of total sales).Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.
Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles*
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.